Most docs able to explain gaps in quality of rheumatology care

Most docs able to explain gaps in quality of rheumatology care
Data from the Physician Quality Reporting System for osteoporosis and rheumatoid arthritis care in Medicare fee-for-service beneficiaries show that up to one-quarter of physicians provided reasons in the system explaining why care was considered but not provided, according to research published in the February issue of Arthritis Care & Research.

(HealthDay)—Data from the Physician Quality Reporting System (PQRS) for osteoporosis and rheumatoid arthritis (RA) care in Medicare fee-for-service beneficiaries show that up to one-quarter of physicians provided reasons in the system explaining why care was considered but not provided, according to research published in the February issue of Arthritis Care & Research.

In an effort to assess the frequency and nature of physician-reported reasons why recommended care was not provided, Jeffrey R. Curtis, M.D., M.P.H., of the University of Alabama in Birmingham, and colleagues used data from the PQRS for 1,775 physicians reporting on one or more measures, and 630 physicians reporting on one or more RA measures.

The researchers found that 76 percent of patients received the recommended dual X-ray absorptiometry osteoporosis screening. Overall, 82 percent of patients with osteoporosis and 89 percent of RA patients received prescription osteoporosis medication or disease-modifying antirheumatic drug/biologic agent, respectively. Physicians provided medical, patient, system, or other reasons why care was considered but not provided for the remaining 11 to 24 percent of RA and osteoporosis patients.

"Our results suggest that the substantial care gaps previously identified in published osteoporosis and RA studies using administrative data may have been somewhat overestimated because of care that was not provided for a presumed valid reason," the authors write. "Allowing physicians the opportunity to provide reasons why they considered but did not provide care appears useful to inform measurement in quality of care and should be an integral part of quality reporting systems in the future."

All of the authors disclosed financial ties to pharmaceutical companies, including Amgen, which partially funded the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Data suggest smoking doesn't impact RA treatment response

Dec 21, 2012

(HealthDay)—For patients with early rheumatoid arthritis (RA), smoking status does not impact treatment response to early combination therapy or initial methotrexate treatment with step-up therapy, according ...

Recommended for you

ACR: Most hospitalizations for gout are preventable

Nov 18, 2014

(HealthDay)—Most hospitalizations for a primary diagnosis of gout are preventable, according to a study presented at the annual meeting of the American College of Rheumatology, held from Nov. 14 to 19 in ...

TNF inhibitors may increase cancer risk in the eye

Nov 17, 2014

One of the family of drugs prescribed for rheumatoid arthritis and other inflammatory conditions is called TNF inhibitors. They act by dampening part of the immune system called tumor necrosis factor (TNF). In one of the ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.